United Therapeutics (BSP:U2TH34) Forward Dividend Yield % : 0.00% (As of Jun. 28, 2025)

View and export this data going back to 2023. Start your Free Trial

What is United Therapeutics Forward Dividend Yield %?

As of today (2025-06-28), the Forward Annual Dividend Yield of United Therapeutics is 0.00%.

As of today (2025-06-28), the Trailing Annual Dividend Yield of United Therapeutics is 0.00%.

BSP:U2TH34's Forward Dividend Yield % is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 1.875
* Ranked among companies with meaningful Forward Dividend Yield % only.

United Therapeutics's Dividends per Share for the three months ended in Mar. 2025 was R$0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Competitive Comparison of United Therapeutics's Forward Dividend Yield %

For the Drug Manufacturers - Specialty & Generic subindustry, United Therapeutics's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

United Therapeutics's Forward Dividend Yield % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, United Therapeutics's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where United Therapeutics's Forward Dividend Yield % falls into.

Save Embed

;

Save Embed

;

United Therapeutics Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.

United Therapeutics (BSP:U2TH34) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.

United Therapeutics Forward Dividend Yield % Related Terms

Thank you for viewing the detailed overview of United Therapeutics's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

United Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » United Therapeutics Corp (BSP:U2TH34) » Definitions » Forward Dividend Yield %

Comparable Companies

Traded in Other Exchanges

UTHR:USA UTH:Germany UTH:Germany

Address

1000 Spring Street, Silver Spring, MD, USA, 20910

Website

https://www.unither.com

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.

United Therapeutics Headlines

No Headlines